Lymphoma, a cancer of the immune system, affects roughly 635,000 people worldwide. Advances in treatment, such as CAR-T cell therapy, have significantly improved survival rates for aggressive lymphomas. CAR-T cell therapy involves collecting and genetically modifying a patient’s T cells to target and destroy lymphoma cells. This innovative personalized treatment has provided hope for patients who have not responded to traditional chemotherapy and antibody-based treatments. Previously, these patients had a poor prognosis, but now there is potential for a cure. Dr. Madiha Iqbal, a Mayo Clinic hematologist and oncologist, explains the process and benefits of CAR-T cell therapy.
Source link
What is CAR-T cell therapy? Oncologist explains
